This work shows the successful reduction of process development time through the implementation of the GSK proprietary platform and the ambr15™ system for a difficult to express protein (Protein A). Protein A is a recombinant enzyme.  The existing bioreactor production process produces low titer in a 21-day production using non-GSK proprietary media platform. These production lengths and titers are not desirable due to availability of manufacturing time in plant, required increase in manufacturing scale, and potential cost of goods. In this poster, we will highlight use of design of experiments and high-throughput screening tools (ambr15™) to quickly identify significant process parameters for improvement. We also utilized GSK’s own proprietary media platform for process improvement, allowing for greater process knowledge and flexibility to enable future cost of goods reduction. Using this platform knowledge and a high-throughput approach, we were able to increase titer 8-fold in 17 days. In addition to improving the titer, we also introduced process changes to closely maintain the original Phase 1 product quality and ensure 100 % enzyme activity in the GSK media platform. <br/>

High throughput development of a difficult to express protein

2019 Spring National Meeting

The official archive and repository for all ACS Meetings & Expositions abstracts and select posters or presentations.